- Home
- CUK vs BIIB Comparison
CUK vs BIIB Comparison
Compare CUK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUK
- BIIB
- Stock Information
- Founded
- CUK 1972
- BIIB 1978
- Country
- CUK United States
- BIIB United States
- Employees
- CUK N/A
- BIIB N/A
- Industry
- CUK Marine Transportation
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CUK Consumer Discretionary
- BIIB Health Care
- Exchange
- CUK Nasdaq
- BIIB Nasdaq
- Market Cap
- CUK 29.8B
- BIIB 25.1B
- IPO Year
- CUK 2000
- BIIB 1991
- Fundamental
- Price
- CUK $23.27
- BIIB $149.94
- Analyst Decision
- CUK Buy
- BIIB Buy
- Analyst Count
- CUK 18
- BIIB 26
- Target Price
- CUK $25.86
- BIIB $248.00
- AVG Volume (30 Days)
- CUK 1.4M
- BIIB 1.6M
- Earning Date
- CUK 12-20-2024
- BIIB 02-11-2025
- Dividend Yield
- CUK N/A
- BIIB N/A
- EPS Growth
- CUK N/A
- BIIB 10.05
- EPS
- CUK 1.44
- BIIB 11.06
- Revenue
- CUK $25,021,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- CUK $7.89
- BIIB N/A
- Revenue Next Year
- CUK $3.41
- BIIB N/A
- P/E Ratio
- CUK $17.41
- BIIB $13.47
- Revenue Growth
- CUK 15.88
- BIIB N/A
- 52 Week Low
- CUK $12.50
- BIIB $145.07
- 52 Week High
- CUK $24.66
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- CUK 50.90
- BIIB 31.81
- Support Level
- CUK $22.93
- BIIB $145.07
- Resistance Level
- CUK $24.64
- BIIB $149.92
- Average True Range (ATR)
- CUK 0.73
- BIIB 3.57
- MACD
- CUK -0.18
- BIIB 0.18
- Stochastic Oscillator
- CUK 30.13
- BIIB 22.27
About CUK Carnival Plc ADS ADS
Carnival is the largest global cruise company, with 92 ships in service at the end of fiscal 2023. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It's currently folding its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 13 million guests in 2019, prior to covid-19, a level it reached again in 2023.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.